Authors: Hashemian SM, Shafigh N, Afzal G, Jamaati H, Tabarsi P, Marjani M PMID: 33358260 PMCID: PMC7834188 DOI: 10.1016/j.pulmoe.2020.10.017 Abstract Background: In December 2019, pneumonia associated with a novel coronavirus (COVID-19) was reported in Wuhan, China. Acute respiratory distress syndrome (ARDS) is the most frequently observed complication in COVID-19 patients with high mortality rates. Objective [...]

Authors: Villa G, Romagnoli S, De Rosa S, Greco M, Resta M PMID: 33046113 PMCID: PMC7549343 DOI: 10.1186/s13054-020-03322-6 Abstract Background: Systemic inflammation in COVID-19 often leads to multiple organ failure, including acute kidney injury (AKI). Renal replacement therapy (RRT) in combination with sequential extracorporeal blood purification therapies (EBP) might support renal function, attenuate systemic inflammation, [...]

This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis.

Authors: Boretti A, Banik BK PMID: 32322486 PMCID: PMC7172861 DOI: 10.1016/j.phanu.2020.100190 Abstract The recent outbreak of Covid19 has required urgent treatments for numerous patients. No suitable vaccines or antivirals are available for Covid19. The efficiency against Covid19 of WHO therapies of choice, that are two antivirals developed for other pathologies, is controversial. Therefore, alternative approaches [...]

Authors: Moore JB, June CH PMID: 32303591 DOI: 10.1126/science.abb8925 Abstract In December 2019, a new strain of coronavirus, severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), was recognized to have emerged in Wuhan, China. Along with SARS-CoV and Middle East respiratory syndrome–coronavirus (MERS-CoV), SARS-CoV-2 is the third coronavirus to cause severe respiratory illness in humans, called coronavirus [...]

Authors: Ye Q, Wang B, Mao J PMID: 32283152 PMCID: PMC7194613 DOI: 10.1016/j.jinf.2020.03.037 Abstract Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration [...]

Authors: McGonagle D, Sharif K, O'Regan A, Bridgewood C PMID: 32251717 PMCID: PMC7195002 DOI: 10.1016/j.autrev.2020.102537 Abstract Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency [...]

Authors: Zhang C, Wu Z, Li JW, Zhao H, Wang GQ PMID: 32234467 PMCID: PMC7118634 DOI: 10.1016/j.ijantimicag.2020.105954 Abstract Since December 2019, a viral pneumonia, named coronavirus disease 2019 (COVID-19), from Wuhan, China, has swept the world. Although the case fatality rate is not high, the number of people infected is large and there is still [...]

Authors: Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ PMID: 32192578 PMCID: PMC7270045 DOI: 10.1016/S0140-6736(20)30628-0 Abstract As of March 12, 2020, coronavirus disease 2019 (COVID-19) has been confirmed in 125 048 people worldwide, carrying a mortality of approximately 3·7%,1 compared with a mortality rate of less than 1% from influenza. There [...]

Authors: Wu D, Yang XO PMID: 32205092 PMCID: PMC7156211 DOI: 10.1016/j.jmii.2020.03.005 Abstract COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type [...]